Myopia is a refractive disorder caused by excessive axial elongation, leading to blurred distance vision. Its development involves genetic, environmental and molecular factors, including retinal N6-methyladenosine (m6A) RNA modification.
Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026.
Zipbio has signed an exclusive license agreement with Meiragtx Holdings plc to advance an AAV gene therapy for geographic atrophy. Under the agreement, Meiragtx will receive exclusive rights to Zipbio’s first-in-class therapies targeting the complement pathway for geographic atrophy.
Alchemedicine Inc. has disclosed complement factor D (CFD) inhibitors described as potentially useful for the treatment of age-related macular degeneration, arthritis, Alzheimer’s disease, multiple sclerosis, ulcerative colitis, diabetic retinopathy, glaucoma and autoimmune diseases.
The presbyopia space gained another player as Tenpoint Therapeutics Ltd. won the U.S. FDA’s go-ahead for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution, 2.75%/0.1%, previously known as Brimochol PF), the first and only dual-agent eye drop for the treatment of adult presbyopia.
Suzhou Raymon Pharmaceuticals Co. Ltd. has identified nitric oxide (NO) donor-containing compounds reported to be useful for the treatment of glaucoma, age-related macular degeneration, diabetic retinopathy, cataract, uveitis, keratitis and ocular hypertension.
Shenzhen Newrosetta Biosciences Co. Ltd. has divulged benzodiazepine derivatives acting as muscarinic M2 receptor antagonists reported to be useful for the treatment of myopia.
Guangzhou Runer Ophthalmic Biotechnology Co. Ltd. has divulged compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy, uveitis, retinitis pigmentosa, atypical hemolytic uremic syndrome, macular edema, membranous glomerulonephritis and paroxysmal nocturnal hemoglobinuria (PNH).
RSS
